NCT02971761: Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer

Breast Cancer Type: Triple Negative
Hormone Mutations: AR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Patients must have AR+ tumor(s)
Exclusions: Patients with active, unstable, or untreated central nervous system metastasis (brain or leptomeningeal disease)

Comments are closed.

Up ↑